![1]()
News
Older IBD patients are most at risk of postdischarge VTE
September 10, 2019
Readmission for venous thromboembolism in patients with inflammatory bowel diseases most often occurs within 60 days of discharge.
![1]()
News
Statins may do double duty as antidepressants
September 10, 2019
COPENHAGEN – Mounting evidence suggests antidepressant efficacy for statins in immunometabolic-related depression.
![1]()
News
ARNIs effective for acute decompensated heart failure
September 9, 2019
In patients hospitalized for acute decompensated heart failure with reduced ejection fraction (HFrEF), is an angiotensin receptor–neprilysin inhibitor (ARNI) as effective as enalapril in reducing levels of N-terminal of the prohormone brain natriuretic peptide (NT-proBNP)?
![1]()
News
Wrong cuff size throws off pediatric BP by 5 mm Hg
September 7, 2019
NEW ORLEANS – The study helps inform the use of a cuff that’s too big or too small when the correct sized cuff is unavailable.
![1]()
News
Predicted risk of cardiac complications varies among risk calculators
September 4, 2019
How frequently is there concordance between three recommended risk calculators in categorizing a patient as low risk for major adverse cardiac event (MACE)?
![1]()
News
POP AGE shakes up DAPT in elderly
September 1, 2019
PARIS – Clopidogrel hailed as P2Y12 inhibitor of choice in older patients with non-ST-elevation ACS.
![1]()
News
FDA’s low-risk TAVR okay set to propel case volume
August 27, 2019
The FDA’s approval of TAVR for low-risk patients should boost both case numbers and U.S. TAVR sites.
![1]()
News
Anticoagulant therapy for AFib in patients with end-stage renal disease
August 23, 2019
Apixaban may be safer than warfarin for patients who have ESRD and who plan for anticoagulation because of AFib.
![1]()
News
Treating children with Kawasaki disease and coronary enlargement
August 22, 2019
An important new study reveals a treatment protocol that decreases the rate of aneurysm enlargement.
News
Dapagliflozin meets primary endpoint in the DAPA-HF trial
August 21, 2019
AstraZeneca announces preliminary results in first heart failure trial in an SGLT2 inhibitor.
